This chapter focuses on vitrification technologies for cryopreservation in human assisted reproductive technology (ART). For cryopreservation of human embryos, PROH and dimethylsulfoxide (DMSO) have been used as the dominant cryoprotective agents (CPAs). There are several protocols that have been introduced for human day 2-3 vitrification. The differences between the protocols are related to the type and concentration of CPAs and duration of exposure of CPAs. The chapter presents a summary of those protocols and clinical outcomes. A large blastocoel might lessen cryopreservative potential due to ice crystal formation during the rapid cooling phase of vitrification. To overcome this problem, shrinkage of the blastocoel was thought to be the appropriate approach. Cryopreservation of human oocytes has been significantly improved by refined slow-freezing methods and new vitrification techniques. In future, vitrification will become the most suitable method for cryopreservation of any cells and tissues.